Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
Steven D. Nathan(Inova Fairfax Hospital), Paul W. Noble(Cedars-Sinai Medical Center), Lisa Lancaster(Vanderbilt University Medical Center), Ian Glaspole(Monash University), Carlo Albera(University of Turin), David J. Lederer(Regeneron (United States)), David Kardatzke(InterScience (United States)), Dominique Valeyre(Inserm), Williamson Z. Bradford(InterScience (United States)), Marilyn K. Glassberg(University of Miami), Ulrich Costabel(Ruhrlandklinik), Carlos A. Pereira(Universidade Federal de São Paulo), Jeffrey J. Swigris(National Jewish Health), Klaus-Uwe Kirchgaessler(Roche (Switzerland)), Monica Daigl(Roche (Switzerland))
Cited by 331
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
|Immunity|2009|2.3k
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
|The Lancet|2011|2.1k
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2006|1.3k